

MedStar Health, Inc.

POLICY AND PROCEDURE MANUAL

Policy Number: MP.031.MH
Last Review Date: 11/30/2017
Effective Date: 1/1/18

MP.031.MH – Shingles Vaccines: Zostavax, Shingrix

This policy applies to the following lines of business:

- ✓ MedStar Employee (Select)
- ✓ MedStar MA – DSNP - CSNP

MedStar Health considers **Shingles Vaccines** medically necessary for the following indications:

*** **NOTE for Medicare:** Zostavax and Shingles vaccines are covered only through the pharmacy benefit. If the HMO or PPO benefit plan includes PART D prescription drug coverage. If the Medicare Advantage benefit plan does **not** include prescription benefits, this vaccine is **not** a covered benefit. Both vaccines are covered under the medical benefit for Commercial/Individual and Medicaid.

ZOSTAVAX VACCINE:

This vaccine is covered **for adults 60 years of age or older.**

Limitations

The following are contraindications for this vaccine:

1. HIV+ members with a CD4+ T lymphocyte count of <200 cells/ μ L
2. Treatment with drugs that affect the immune system, such as steroids
3. Members who have a weakened immune system because of:
 - a. Cancer treatment such as radiation or chemotherapy
 - b. Cancer affecting the bone marrow or lymphatic system, such as leukemia or lymphoma
4. Pregnancy or nursing mothers (Pregnancy should be avoided for three months post vaccination)
5. Active tuberculosis
6. History of anaphylactic/anaphylactoid reaction to gelatin, neomycin or any other component of the vaccine
7. The vaccine should not be used in children
8. The vaccine should not be used for treatment of Zoster or PHN

SHINGRIX VACCINE:

This vaccine is indicated for prevention of herpes zoster (shingles) in **adults aged 50 years and older.** It is not indicated for prevention of primary varicella infection (chickenpox).

MP.031.MH – Shingles Vaccines: Zostavax, Shingrix

Policy Number: MP.031.MH

Last Review Date: 11/30/2017

Effective Date: 1/1/18

Limitations:

Shingrix should not be administered to:

1. A person with a history of severe allergic reaction, such as anaphylaxis, to any component of a vaccine or after a previous dose of Shingrix
2. A person who is known to be seronegative for varicella
3. A person experiencing an acute episode of herpes zoster. Shingrix is not a treatment for herpes zoster or postherpetic neuralgia (PHN). The general guidance for any vaccine is to wait until the acute stage of the illness is over and symptoms abate.
4. Shingrix has not been studied in pregnant women or women who are breastfeeding. Providers should consider delaying Shingrix vaccination for these women.
5. Adults with a minor acute illness, such as a cold, can receive Shingrix. Adults with a moderate or severe acute illness should usually wait until they recover before getting the vaccine. This includes anyone with a temperature of 101.3°F or higher

Background

Shingles, also known as herpes zoster or varicella zoster, is caused by reactivation of the dormant varicella-zoster virus (VZV). VZV is the same virus that causes chickenpox and stays in the body for life. Anyone who has been infected by chickenpox could develop shingles, though not all will. With increasing age and a weakened immunity to VZV, the virus can reactivate causing painful blisters typically on one side of the body. Shingles is most common in people 50 years of age and older and risk of complications increases with age. Common symptoms associated with shingles includes itching and painful rashes, typically presented as clusters of blisters in a single area of the body. Shingles can lead to complications such as post-herpetic neuralgia (PHN), a persistent nerve pain occurring after the rash has healed.

According to the CDC, the new shingles vaccine called Shingrix was licensed by the U.S. Food and Drug Administration (FDA) in 2017. CDC recommends that healthy adults 50 years and older get two doses of Shingrix, 2 to 6 months apart. Shingrix provides strong protection against shingles and PHN. Shingrix is the preferred vaccine, over Zostavax, a shingles vaccine in use since 2006.

Codes:

CPT Codes / HCPCS Codes / ICD-10 Codes	
Code	Description
90736 (Zostavax)	Zoster vaccine live for subcutaneous use.
90750 (Shingrix)	Zoster (shingles) vaccine (HZV), recombinant, sub-unit, adjuvanted, for intramuscular use

Variations

MP.031.MH – Shingles Vaccines: Zostavax, Shingrix

Policy Number: MP.031.MH

Last Review Date: 11/30/2017

Effective Date: 1/1/18

References

1. Center for Disease Control and Prevention (CDC): Advisory Committee on Immunization Practices (ACIP) Recommended Adult Immunization Schedule for Adults Aged 19 years and Older, United States – 2013. MMWR. 2013 Feb; 62(01):9-19. <http://www.cdc.gov/mmwr/preview/mmwrhtml/su6201a3.htm>
2. Centers for Disease Control and Prevention (CDC): Prevention of Herpes Zoster. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR. 2008 June 6; 57(RR-5). <http://www.cdc.gov/mmwr/PDF/rr/rr5705.pdf>
3. Centers for Disease Control and Prevention (CDC): Update on Recommendation for Use of Herpes Zoster Vaccine. MMWR. 2014 Aug; 63(33);729-731. <http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6333a3.htm>
4. Centers for Disease Control and Prevention CDC: Shingle Vaccine Information Sheet (VIS). Current date: 10/6/2009. <http://www.cdc.gov/vaccines/hcp/vis/vis-statements/shingles.html>
5. Centers for Disease Control and Prevention: Shingrix Recommendations. February 7, 2018. <https://www.cdc.gov/vaccines/vpd/shingles/hcp/shingrix/recommendations.html>
6. Centers for Medicare and Medicaid Services (CMS). Medicare Learning Network (MLN) Matters No. SE0678.: Payment for Part D Vaccines under the Medicare Drug Benefit (Part D). . <http://www.cms.gov/Outreach-and-Education/Medicare-Learning-Network-MLN/MLNMattersArticles/downloads/se0678.pdf>
7. Dooling KL, Guo A, Patel M, et al. Recommendations of the Advisory Committee on Immunization Practices for Use of Herpes Zoster Vaccines. MMWR Morb Mortal Wkly Rep 2018;67:103–108. DOI: <http://dx.doi.org/10.15585/mmwr.mm6703a5>
8. Merck & Co., Inc. ZOSTAVAX® [Zoster Vaccine, Live, (Oka/Merck)]. Product Information, Accessed 10/28/2015. <https://www.merckvaccines.com/Products/Zostavax/Pages/home>
9. Oxman MN, Levin MJ, Johnson GR, et al., A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med. 2005 June; 352(22):2271-2284. <http://www.nejm.org/doi/pdf/10.1056/NEJMoa051016>
10. Schmader KE, Levin MJ, Gnann JW, et al. Efficacy, safety, and tolerability of Herpes Zoster vaccine in persons aged 50-59 years. Clin Infect Dis. 2012 Apr; 54(7), 922-928. <http://cid.oxfordjournals.org/content/54/7/922.full.pdf+html>
11. U.S. Food and Drug Administration (FDA). Approval Letter – Zostavax. STN: BL 125123/0. Dated May 25, 2006. <http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm132873.htm>
12. U.S. Food and Drug Administration (FDA). Approval Letter – Zostavax. STN: BL 125123/734. Dated March 24, 2011.

MP.031.MH – Shingles Vaccines: Zostavax, Shingrix

Policy Number: MP.031.MH

Last Review Date: 11/30/2017

Effective Date: 1/1/18

<http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm248608.htm>

13. U.S. Food and Drug Administration (FDA). FDA News Release: FDA Licenses New Vaccine to Reduce Older Americans' Risk of Shingles, May 26, 2006. P06-73.

<http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2006/ucm108659.htm>

14. Voelker R. FDA expands age range for shingles vaccine. JAMA. 2011 Apr; 305(15): 1526. <http://jama.jamanetwork.com/article.aspx?articleid=897078>

Disclaimer:

MedStar Health medical payment and prior authorization policies do not constitute medical advice and are not intended to govern or otherwise influence the practice of medicine. The policies constitute only the reimbursement and coverage guidelines of MedStar Health and its affiliated managed care entities. Coverage for services varies for individual members in accordance with the terms and conditions of applicable Certificates of Coverage, Summary Plan Descriptions, or contracts with governing regulatory agencies.

MedStar Health reserves the right to review and update the medical payment and prior authorization guidelines in its sole discretion. Notice of such changes, if necessary, shall be provided in accordance with the terms and conditions of provider agreements and any applicable laws or regulations.

These policies are the proprietary information of Evolent Health. Any sale, copying, or dissemination of said policies is prohibited.